Mostrar el registro sencillo del ítem

dc.contributor.authorPiña, María Jesús
dc.contributor.authorGirotti, Alessandra
dc.contributor.authorSantos García, María Mercedes 
dc.contributor.authorRodríguez Cabello, José Carlos 
dc.contributor.authorArias Vallejo, Francisco Javier 
dc.date.accessioned2016-12-14T09:29:10Z
dc.date.available2016-12-14T09:29:10Z
dc.date.issued2016
dc.identifier.citationMolecular Pharmaceutics, American Chemical, 2016, vol. 7; 13; (3) p. 795-808es
dc.identifier.issn1543-8384es
dc.identifier.urihttp://uvadoc.uva.es/handle/10324/21697
dc.descriptionProducción Científicaes
dc.description.abstractThe search for new and biocompatible materials with high potential for improvement is a challenge in gene delivery applications. A cell type specific vector made of elastin- like recombinamer (ELR) and aptamers has been specifically designed for the intracellular delivery of therapeutic material for breast cancer therapy. A lysine-enriched ELR was constructed and complexed with plasmid DNA to give positively charged and stable polyplexes. Physical character- ization of these polyplexes showed a particle size of around 140 nm and a zeta potential of approximately +40 mV. The incorporation of MUC1-specific aptamers into the polyplexes resulted in a slight decrease in zeta potential but increased cell transfection specificity for MCF-7 breast cancer cells with respect to a MUC1-negative tumor line. After showing the transfection ability of this aptamer-ELR vector which is facilitated mainly by macropinocytosis uptake, we demonstrated its application for suicide gene therapy using a plasmid containing the gene of the toxin PAP-S. The strategy developed in this work about using ELR as polymeric vector and aptamers as supplier of specificity to deliver therapeutic material into MUC1-positive breast cancer cells shows promising potential and continues paving the way for ELRs in the biomedical field.es
dc.format.mimetypeapplication/pdfes
dc.language.isoenges
dc.publisherAmerican Chemical Societyes
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectCáncer-Terapiases
dc.titleBiocompatible ELR-Based Polyplexes Coated with MUC1 Specific Aptamers and Targeted for Breast Cancer Gene Therapyes
dc.typeinfo:eu-repo/semantics/articlees
dc.identifier.doi10.1021/acs.molpharmaceut.5b00712es
dc.relation.publisherversionpubs.acs.org/molecularpharmaceuticses
dc.identifier.publicationfirstpage795es
dc.identifier.publicationlastpage808es
dc.identifier.publicationtitleMolecular Pharmaceuticses
dc.identifier.publicationvolumeVol. 7;13 (3)es
dc.peerreviewedSIes
dc.description.projectEste trabajo forma parte de los Proyectos de Investigación financiados por la Comisión Europea a través del Fondo Social Europeo (FSE) y de la Consejería de Educación mediante el Fondo Europeo de Desarrollo Regional (ERDF), el MINECO (Proyectos MAT2013-41723-R, MAT2013-42473-R, PRI−PIBAR-2011-1403 y MAT2012-38043), la Junta de Castilla y León (Proyectos VA155A12, VA152A12, and VA244U13), el CIBER-BBN y el Instituto de Salud Carlos III mediante el Centro de Medicina Regenerativa y Terapia Celular de Castilla y León.es
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International


Ficheros en el ítem

Thumbnail
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem